18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
(ARGOS Trial)
Recruiting in Palo Alto (17 mi)
+53 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Allergan
No Placebo Group
Trial Summary
What is the purpose of this trial?
Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Research Team
AI
ALLERGAN INC.
Principal Investigator
Allergan
Eligibility Criteria
Inclusion Criteria
- Patient diagnosed with OAG or OHT who is scheduled to receive a bimatoprost intracameral implant in at least one eye.
Treatment Details
Interventions
- Bimatoprost Intracameral Implant (DURYSTA) (Prostaglandin Analog)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Bimatoprost intracameral implant (DURYSTA) 10μgExperimental Treatment0 Interventions
Patients with OAG or OHT who are scheduled for intracameral administration of a bimatoprost intracameral implant by their ophthalmologist.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Allergan
Lead Sponsor
Trials
782
Recruited
277,000+
Brent Saunders
Allergan
Chief Executive Officer since 2015
JD and MBA from Temple University
Dr. David Nicholson
Allergan
Chief Medical Officer since 2015
MD from Harvard Medical School